High levels of tissue plasminogen activator (tPA) antigen precede the development of type 2 diabetes in a longitudinal population study. The Northern Sweden MONICA Study

Cardiovascular Diabetology

Volumn 2, Issue , 2003, Pages

  Eliasson, Mats C E ^a,b   Jansson, Jan Håkan ^a,c   Lindahl, Bernt ^a   Stegmayr, Brigitta ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b SUNDERBY HOSPITAL   (Sweden)

^c Skelleftea Hospital   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; PLASMINOGEN ACTIVATOR INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL;

ADULT; ANTHROPOMETRY; ARTICLE; CLINICAL STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ENDOTHELIUM; ENZYME ACTIVITY; FEMALE; FIBRINOLYSIS; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GROUPS BY AGE; GROUPS BY SEX; HUMAN; INCIDENCE; INSULIN BLOOD LEVEL; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PREDICTION; RISK ASSESSMENT; SWEDEN; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 2942521622     PISSN: 14752840     EISSN: None     Source Type: Journal    
DOI: 10.1186/1475-2840-2-19     Document Type: Article

References (34)

1. Eliasson M, Lindahl B, Lundberg V, Stegmayr B: Diabetes and obesity in northern Sweden - occurence and risk factor for stroke and myocardial infarction. Scand J Publ Health 2003, 31: 70-77.
2. UK Prospective Diabetes Study 6. Complications in newly diagnosed type 2 diabetic patients and their association with different clinical and biochemical risk factors. Diabetes Res 1990, 13:1-11.
3. DECODE Study Group: Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001, 161:397-405.
4. Lundblad D, Eliasson M: Silent myocardial infarction in women with impaired glucose tolerance: The Northern Sweden MONICA study. Cardiovasc Diabetol 2003, 2:9.
5. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK: Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 1990, 263:2893-2898.
6. Jarrett RJ, Shipley MJ: Type 2 (non-insulin-dependent) diabetes mellitus and cardiovascular disease-putative association via common antecedents; further evidence from the Whitehall Study. Diabetologia 1988, 31:737-740.
7. Stern MP: Diabetes and cardiovascular disease. The "common soil" hypothesis. Diabetes 1995, 44:369-374.
8. Festa A, D'Agostino R., Jr., Tracy RP, Haffner SM: Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2002, 51:1131-1137.
9. Freeman DJ, Norrie J, Caslake MJ, Gaw A, Ford I, Lowe GD, O'Reilly DS, Packard CJ, Sattar N: C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 2002, 51:1596-1600.
10. Han TS, Sattar N, Williams K, Gonzalez-Villalpando C, Lean ME, Haffner SM: Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care 2002, 25:2016-2021.
11. Thorand B, Lowel H, Schneider A, Kolb H, Meisinger C, Frohlich M, Koenig W: C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg cohort study, 1984-1998. Arch Intern Med 2003, 163:93-99.
12. Nakanishi S, Yamane K, Kamei N, Okubo M, Kohno N: Elevated Creactive protein is a risk factor for the development of type 2 diabetes in Japanese americans. Diabetes Care 2003, 26:2754-2757.
13. Krakoff J, Funahashi T, Stehouwer CD, Schalkwijk CG, Tanaka S, Matsuzawa Y, Kobes S, Tataranni PA, Hanson RL, Knowler WC, Lindsay RS: Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian. Diabetes Care 2003, 26:1745-1751.
14. Duncan BB, Schmidt MI, Offenbacher S, Wu KK, Savage PJ, Heiss G: Factor VIII and other hemostasis variables are related to incident diabetes in adults. The Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care 1999, 22:767-772.
15. Hamsten A, Wiman B, de Faire U, Blomback M: Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985, 313:1557-1563.
16. Thogersen AM, Jansson JH, Boman K, Nilsson TK, Weinehall L, Huhtasaari F, Hallmans G: High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1998, 98:2241-2247.
17. Ladenvall P, Johansson L, Jansson JH, Jern S, Nilsson TK, Tjarnlund A, Jern C, Boman K: Tissue-type plasminogen activator -7,351C/T enhancer polymorphism is associated with a first myocardial infarction. Thromb Haemost 2002, 87:105-109.
18. Jansson JH, Nilsson TK, Olofsson BO: Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris. Eur Heart J 1991, 12:157-161.
19. Jansson JH, Olofsson BO, Nilsson TK: Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease. A 7-year follow-up. Circulation 1993, 88:2030-2034.
20. Stegmayr B, Lundberg V, Asplund K: The event registration and survey procedures in the Northern Sweden MONICA Project. Scand J Publ Health 2003, 31: 9-17.
21. Eliasson M, Asplund K, Evrin PE, Lindahl B, Lundblad D: Hyperinsulinemia predicts low tissue plasminogen activator activity in a healthy population: the Northern Sweden MONICA Study. Metabolism 1994, 43:1579-1586.
22. Eliasson M, Lindahl B, Lundberg V, Stegmayr B: No increase in the prevalence of known diabetes between 1986 and 1999 in subjects 25-64 years of age in northern Sweden. Diabet Med 2002, 19:874-880.
23. World Health Organisation: Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO consultation Part 1: Diagnosis and classification of diabetes mellitus. Geneva, WHO/NCD/NCS/99.2; 1999.
24. Eliasson M, Evrin PE, Lundblad D, Asplund K, Rånby M: Influence of gender, age and sampling time on plasma fibrinolytic variables and fibrinogen. Fibrinolysis 1993, 7:316-323.
25. Welborn TA, Garcia-Webb P, Bonser A, McCann V, Constable I: Clinical criteria that reflect C-peptide status in idiopathic diabetes. Diabetes Care 1983, 6:315-316.
26. Eliasson M, Evrin PE, Lundblad D: Fibrinogen and fibrinolytic variables in relation to anthropometry, lipids and blood pressure. The Northern Sweden MONICA Study. J Clin Epidemiol 1994, 47:513-524.
27. Krebs M, Geiger M, Polak K, Vales A, Schmetterer L, Wagner OF, Waldhausl W, Binder BR, Roden M: Increased plasma levels of plasminogen activator inhibitor-1 and soluble vascular cell adhesion molecule after triacylglycerol infusion in man. Thromb Haemost 2003, 90:422-428.
28. Stehouwer CD, Gall MA, Twisk JW, Knudsen E, Emeis JJ, Parving HH: Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes 2002, 51:1157-1165.
29. Eliasson M, Jansson JH, Nilsson P, Asplund K: Increased levels of tissue plasminogen activator antigen in essential hypertension. A population-based study in Sweden. J Hypertens 1997, 15:349-356.
30. Diamond SL, Eskin SG, McIntire LV: Fluid flow stimulates tissue plasminogen activator secretion by cultured human endothelial cells. Science 1989, 243:1483-1485.
31. Iba T, Sumpio BE: Tissue plasminogen activator expression in endothelial cells exposed to cyclic strain in vitro. Cell Transplant 1992, 1:43-50.
32. Salame MY, Samani NJ, Masood I, deBono DP: Expression of the plasminogen activator system in the human vascular wall. Atherosclerosis 2000, 152:19-28.
33. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD: Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 1996, 97:2601-2610.
34. Baron AD: The coupling of glucose metabolism and perfusion in human skeletal muscle. The potential role of endothelium-derived nitric oxide. Diabetes 1996, 45:S105-9.